These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35622255)

  • 1. Peculiarities of Humoral Immunity Formation in Medical Institution Employees Recovered from or Vaccinated against COVID-19 in Irkutsk.
    Dubrovina VI; Bryukhova DD; Kiseleva NO; Chesnokova MV; Korytov KM; Pyatidesyatnikova AB; Vishnyakov VA; Balakhonov SV
    Bull Exp Biol Med; 2022 May; 173(1):54-58. PubMed ID: 35622255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.
    Rastawicki W; Płaza K
    Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.
    Popova AY; Smirnov VS; Andreeva EE; Babura EA; Balakhonov SV; Bashketova NS; Bugorkova SA; Bulanov MV; Valeullina NN; Vetrov VV; Goryaev DV; Detkovskaya TN; Ezhlova EB; Zaitseva NN; Istorik OA; Kovalchuk IV; Kozlovskikh DN; Kombarova SY; Kurganova OP; Lomovtsev AE; Lukicheva LA; Lyalina LV; Melnikova AA; Mikailova OM; Noskov AK; Noskova LN; Oglezneva EE; Osmolovskaya TP; Patyashina MA; Penkovskaya NA; Samoilova LV; Stepanova TF; Trotsenko OE; Totolian AA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.
    Budziar W; Gembara K; Harhala M; Szymczak A; Jędruchniewicz N; Baniecki K; Pikies A; Nahorecki A; Hoffmann A; Kardaś A; Szewczyk-Dąbrowska A; Klimek T; Kaźmierczak Z; Witkiewicz W; Barczyk K; Dąbrowska K
    PLoS One; 2022; 17(2):e0253638. PubMed ID: 35113873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2 antibodies in the county town of Slovakia - a pilot study from the Trencin city.
    Kajanova I; Grossmannova K; Jelenska L; Lukacikova L; Radikova Z; Knutova N; Nahlikova J; Belisova M; Pastorekova S; Kopacek J
    Acta Virol; 2022; 66(3):228-237. PubMed ID: 35850521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses.
    Yang Y; Wang X; Du RH; Zhang W; Si HR; Zhu Y; Shen XR; Li Q; Li B; Men D; Zhou YN; Wang H; Tong XL; Zhang XE; Shi ZL; Zhou P
    Emerg Microbes Infect; 2021 Dec; 10(1):905-912. PubMed ID: 33870851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic.
    Brehm TT; Thompson M; Ullrich F; Schwinge D; Addo MM; Spier A; Knobloch JK; Aepfelbacher M; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
    Int J Hyg Environ Health; 2021 Sep; 238():113851. PubMed ID: 34601375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
    Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L
    BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.
    Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG
    BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.
    Barchuk A; Skougarevskiy D; Kouprianov A; Shirokov D; Dudkina O; Tursun-Zade R; Sergeeva M; Tychkova V; Komissarov A; Zheltukhina A; Lioznov D; Isaev A; Pomerantseva E; Zhikrivetskaya S; Sofronova Y; Blagodatskikh K; Titaev K; Barabanova L; Danilenko D
    PLoS One; 2022; 17(6):e0266945. PubMed ID: 35704649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroprevalence of SARS-CoV-2 IgG antibodies in the staff of the Slovak Academy of Sciences in response to COVID-19 and/or vaccination: situation in August 2021.
    Kajanova I; Lukacikova L; Jelenska L; Grossmannova K; Radikova Z; Vlcek M; Klempa B; Kollar R; Bodova K; Kopacek J; Pastorekova S
    Acta Virol; 2021; 65(4):420-432. PubMed ID: 34796716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Seroprevalence of SARS-CoV-2 Antibodies among HealthCare Workers in University Hospital in Krakow before the Era of Vaccination.
    Żółtowska B; Barańska I; Jachowicz E; Sydor W; Maziarz B; Mydel K; Różańska A; Wizner B; Rosiński J; Kossowska M; Głomb K; Wójkowska-Mach J
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare workers highly affected during the COVID-19 epidemic wave in Poland prior to vaccination availability: seroprevalence study.
    Rosińska M; Stępień M; Kitowska W; Milczarek M; Juszczyk G; Nowacka Z; Gardel A; Hermann A; Bardoń-Błaszkowska A; Cudnik R; Czubak H; Wolniak-Bińkowska M; Źródłowska IA; Sadkowska-Todys M
    Med Pr; 2022 Apr; 73(2):109-123. PubMed ID: 35301511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: "Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2" by Krsak
    Mishra BK; Bhattacharya D; Kshatri JS; Pati S
    Viral Immunol; 2021 Nov; 34(9):658. PubMed ID: 34672807
    [No Abstract]   [Full Text] [Related]  

  • 19. SARS-CoV-2 seroprevalence in healthcare workers of a teaching hospital in a highly endemic region in the Netherlands after the first wave: a cross-sectional study.
    Bouwman M; van Osch F; Crijns F; Trienekens T; Mehagnoul-Schipper J; van den Bergh JP; de Vries J
    BMJ Open; 2021 Oct; 11(10):e051573. PubMed ID: 34663664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.